Qlife Holding AB (QLIFE)

Overview

Qlife Holding AB (publ) stands out in the med-tech industry as a pioneering company, focusing on the design, manufacturing, and marketing of in-vitro diagnostic analyzers along with corresponding reagents. Established in 2019, with a strategic base in Helsingborg, Sweden, Qlife has carved a niche for itself by introducing the Egoo.Health Platform. This integrated solution features a unique measurement instrument, paired with disposable capsules and sophisticated software, designed to streamline the process of biomarker and virus testing. The essence of Qlife's mission is to offer advanced, yet user-friendly diagnostic solutions that cater to the evolving needs of healthcare providers and patients alike.

Products and Services

• Egoo.Health Platform

  This flagship offering from Qlife Holding AB revolutionizes the way diagnostic tests are performed. Combining a compact measuring instrument with single-use capsules, the Egoo.Health Platform is engineered for convenience and efficiency. Each capsule is preloaded with a specific test that targets a particular biomarker or virus, making the platform highly versatile for various diagnostic needs. The integrated software ensures seamless operation, from test execution to result analysis, embodying the cutting-edge of healthcare technology.

• C-reactive protein Tests

  As part of their diagnostic repertoire, Qlife provides tests for C-reactive protein (CRP), a significant biomarker for inflammation and infection in the body. These tests are crucial for clinicians to evaluate and manage patients' inflammatory conditions and are seamlessly integrated into the Egoo.Health Platform's capabilities.

• PHE/Phenylalanine Tests for PKU Patients

  Recognizing the need for specialized diagnostics, Qlife has developed tests specifically designed for patients with Phenylketonuria (PKU). These tests measure levels of Phenylalanine (PHE), enabling healthcare providers to monitor and adjust dietary requirements for individuals managing PKU. Utilizing the Egoo.Health Platform, these tests offer a simplified yet effective means of ongoing PKU management.

• Sars-CoV-2/Influenza Multiplex Tests

  In response to the global demand for accurate and timely viral testing, Qlife has introduced multiplex tests capable of detecting Sars-CoV-2 and Influenza viruses concurrently. This innovation is especially relevant in the context of the COVID-19 pandemic and seasonal influenza outbreaks, facilitating efficient diagnosis and aiding in the strategic public health response to viral infections. Integrated within the Egoo.Health Platform, these tests embody Qlife's commitment to addressing urgent healthcare challenges through technology.